Full Press Release Details
argenx files registration statement for a proposed public offering in the United States.
ARGX
argenx files registration statement for a proposed public offering in the United States
Key Takeaway: argenx files registration statement for a proposed public offering in the United States
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
4%
average across 14 past catalysts
Lead asset
Empasiprubart
Phase 2 · Dermatomyositis